Three Seasons Wealth LLC Purchases New Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Three Seasons Wealth LLC bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 2,501 shares of the medical research company's stock, valued at approximately $1,302,000.

Several other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in Thermo Fisher Scientific by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 33,249,575 shares of the medical research company's stock valued at $17,297,426,000 after buying an additional 196,864 shares in the last quarter. Capital World Investors boosted its position in shares of Thermo Fisher Scientific by 1.1% in the fourth quarter. Capital World Investors now owns 9,430,120 shares of the medical research company's stock valued at $4,905,812,000 after acquiring an additional 104,343 shares during the period. Geode Capital Management LLC boosted its position in shares of Thermo Fisher Scientific by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 7,857,385 shares of the medical research company's stock valued at $4,075,540,000 after acquiring an additional 197,442 shares during the period. Norges Bank bought a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $3,149,754,000. Finally, Franklin Resources Inc. boosted its position in shares of Thermo Fisher Scientific by 5.7% in the third quarter. Franklin Resources Inc. now owns 4,853,133 shares of the medical research company's stock valued at $2,935,377,000 after acquiring an additional 262,062 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Barclays dropped their target price on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Evercore ISI dropped their target price on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Wells Fargo & Company dropped their target price on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a research report on Thursday, April 24th. Royal Bank of Canada decreased their price target on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Finally, Robert W. Baird decreased their price target on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Five research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $610.27.

Thermo Fisher Scientific Trading Down 0.1 %

Thermo Fisher Scientific stock traded down $0.64 during mid-day trading on Wednesday, reaching $426.89. 863,952 shares of the company traded hands, compared to its average volume of 1,749,298. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The firm's 50 day moving average price is $482.87 and its 200 day moving average price is $524.80. The firm has a market capitalization of $161.15 billion, a price-to-earnings ratio of 25.83, a P/E/G ratio of 2.99 and a beta of 0.86. Thermo Fisher Scientific Inc. has a 52-week low of $409.85 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. During the same quarter in the previous year, the business posted $5.11 EPS. The company's quarterly revenue was up .2% on a year-over-year basis. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date was Friday, March 14th. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's payout ratio is 10.09%.

Insider Activity

In other news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the sale, the executive vice president now owns 16,363 shares in the company, valued at approximately $9,582,009.17. The trade was a 1.80 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the sale, the senior vice president now directly owns 10,816 shares in the company, valued at $5,759,736.32. This trade represents a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,900 shares of company stock worth $13,106,062. Corporate insiders own 0.33% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.